4 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 5 Phase 2, 4 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 1 | 4 | Active not recruiting 2, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow RNA, Small Interfering: new trials by email Literature Review of RNA, Small Interfering trials Research Report on RNA, Small Interfering
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| siRNA Microneedle Patches for Ear Keloid Post-Surgical Scars Small interfering RNA (siRNA) Microneedle Patches, Carbon Dioxide (CO2) Laser Surgery, Intralesional Triamcinolone 40 mg/mL - Keloid of Ear Lobe | Phase 2 | Not yet recruiting | Ong Kim Yao | 158 | 2026-06-01 | 2026-07-06 |
| Phase 2 Study of ADX-038 in Participants With Geographic Atrophy ADX-038, Placebo - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 240 | 2025-11-10 | 2026-09-03 |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE ADX-324, Placebo - Hereditary Angioedema, HAE | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2025-08-28 | 2026-09-10 |
| Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD) Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA) - Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | Completed | Sanofi | 4545 | 2025-02-17 | 2026-09-08 | |
| A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. Inclisiran sodium, BPA - Hypercholesterolemia | Phase 4 | Completed | Novartis Pharmaceuticals | 402 | 2024-06-21 | 2026-07-29 |
| Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension ADX-850, Placebo - Hypertension, Hypertension,Essential | Phase 1 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 28 | 2024-03-21 | 2026-09-03 |
| Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients ADX-038, Placebo - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 / Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 50 | 2023-08-07 | 2026-06-16 |
| Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients ADX-324, Placebo - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 53 | 2022-12-14 | 2026-06-16 |
| A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531) - Hepatitis B, Chronic | Phase 2 | Completed | Hoffmann-La Roche | 281 | 2020-07-05 | 2025-09-19 |
| Treatment of Chronic Lymphocytic Leukemia shRNA - Leukemia, Lymphocytic, Chronic, B-Cell | Unknown | Peking University People's Hospital | 70 | 2016-12-01 | 2016-05-13 | |
| Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients QPI-1007 at various doses - Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy | Phase 1 | Completed | Quark Pharmaceuticals | 48 | 2010-02-01 | 2013-05-13 |
Angioedemas, Hereditary (2) · Atherosclerosis (1) · Cicatrix (1) · Essential Hypertension (1) · Hemoglobinuria, Paroxysmal (1) · Hepatitis B, Chronic (1) · Hypercholesterolemia (1) · Hypertension (1) · Keloid (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Optic Atrophy (1) · Optic Atrophy, Hereditary, Leber (1) · Optic Neuritis (1) · Optic Neuropathy, Ischemic (1) · Retinal Degeneration (1)
ADARx Pharmaceuticals, Inc. (5) · Hoffmann-La Roche (1) · Novartis Pharmaceuticals (1) · Ong Kim Yao (1) · Peking University People's Hospital (1) · Quark Pharmaceuticals (1) · Sanofi (1)
Australia (5) · United Kingdom (4) · United States (4) · Canada (3) · Germany (3) · Spain (3) · Austria (2) · Bulgaria (2) · China (2) · Czechia (2) · France (2) · Hong Kong (2) · Hungary (2) · Israel (2) · Italy (2)
Lauge Farnaes, MD (2) · Rabia Ozden, MD (1) · Suzanne Wei Na Cheng (1) · Wendy Murahashi (1) · Xiao-Jun Huang (1)
2019 (1)